statementSaid on 2026-11-11

Simcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.

A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.

先聲藥業選擇了一條國際合作路線,與德國Vivoryon合作在中國開發SIM0408,靶向神經毒性澱粉樣蛋白N3pE(pGlu-Aβ),已獲CDE批准進入臨床。
stockintelligencenewsPublished 2026-11-11 Read source

Discussion

0/2000

Related claims

SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.先聲藥業集團 · investigationXinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in China for Phase II clinical trials; Gaoguang Pharmaceutical's brain-penetrant TYK2/JAK1 inhibitor TLL-041 is positioned as a neurodegenerative disease candidate with global first-in-class potential.post author · statementAfter acquiring a controlling stake in Green Valley Pharmaceutical, Fosun incorporated sodium oligomannate capsules, used for mild to moderate Alzheimer's disease, into its innovative drug pipeline and took over its post-marketing confirmatory clinical study.post author · statementThe self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.post author · statementCM383 has started Phase Ib clinical trials for mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease, and some brokerages regard it as a potential leading Aβ antibody in China; CM559 has also advanced to Phase I clinical trials.post author · statementLY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.post author · statement